Metrolina Medical Research Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2011
NCT01328379
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

cd07805/47 (1 trial)

dalfampridine (ampyra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Erythema (Phase 3)

Multiple Sclerosis (Phase 3)

Rosacea (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2